This consent order formalizes a series of procedural deadline extensions in the ongoing banking litigation between Bank of Baroda and the Neopharma/NMC Healthcare group, ensuring the orderly progression of evidence and witness testimony.
Why did Bank of Baroda (DIFC Branch) initiate CFI 043/2020 against Neopharma LLC, NMC Healthcare LLC, New Medical Centre LLC, and Bavaguthu Raghuram Shetty?
The lawsuit concerns a high-stakes banking and finance dispute involving Bank of Baroda (DIFC Branch) and several corporate entities associated with the NMC Healthcare group, alongside Bavaguthu Raghuram Shetty. While the specific underlying debt obligations are not detailed in this procedural order, the litigation involves complex claims typical of the restructuring and recovery efforts following the financial difficulties faced by the NMC group. The current procedural posture involves multiple pending applications—specifically Application 1 (CFI-043-2020/12) and Application 2 (CFI-043-2020/11)—which necessitated a formal adjustment of the litigation timetable to ensure all parties could adequately respond to evidentiary filings.
The dispute is characterized by the need for rigorous evidentiary production, as evidenced by the court's focus on witness statements and replies. The parties reached a consensus to manage these deadlines through a formal order, avoiding the need for contested hearings on procedural delays. As noted in the order:
The time frame for the Claimant to file and serve its evidence in answer to Application 1 and Application 2 shall be extended to 18 April 2023.
This adjustment reflects the court’s role in facilitating the orderly exchange of information in a multi-party, high-value financial dispute, ensuring that the substantive issues regarding the alleged liabilities can be adjudicated on a complete record.
Which DIFC Court official issued the consent order in CFI 043/2020 on 25 April 2023?
The consent order was issued by Assistant Registrar Delvin Sumo within the DIFC Court of First Instance. The order was processed following a series of procedural developments, including the filing of Application 1 and Application 2 by the First and Fourth Defendants, respectively, in late March 2023, and subsequent directions from the Registry on 19 April 2023.
What specific procedural arguments did the First and Fourth Defendants advance regarding the filing of witness statements in CFI 043/2020?
The First Defendant, Neopharma LLC, and the Fourth Defendant, Bavaguthu Raghuram Shetty, sought specific extensions to address the Claimant’s evidentiary submissions. By filing Application 1 and Application 2, the Defendants signaled a need for additional time to review and respond to the Claimant’s witness statements. The parties’ positions were aligned in their request for a structured extension, which the court formalized to ensure compliance with the Rules of the DIFC Courts (RDC). The Defendants’ argument centered on the necessity of filing a formal reply to the Claimant's witness evidence, as stipulated by RDC Rule 23.41, to maintain procedural fairness.
What was the jurisdictional and procedural question the court had to resolve regarding the extension of evidence deadlines?
The primary issue before the court was whether to grant a consensual extension of time for the filing of evidence and witness statements, given the complexity of the ongoing litigation and the pending applications. The court had to determine if the proposed timeline, which pushed deadlines into May and June 2023, remained consistent with the overriding objective of the RDC to deal with cases justly and at a proportionate cost. The court was required to exercise its case management powers to ensure that the extensions did not unduly prejudice the litigation timeline while acknowledging the parties' mutual agreement to the new schedule.
How did the DIFC Court apply the RDC Part 29 requirements to the witness statement filing timeline?
The court exercised its authority under the RDC to manage the production of witness evidence, ensuring that both factual witness statements and subsequent reply statements were governed by a clear, enforceable schedule. By incorporating the requirements of RDC Part 29 into the consent order, the court ensured that the parties’ evidentiary submissions would meet the formal standards required for admissibility and procedural integrity. The court’s reasoning focused on providing sufficient time for the parties to prepare their respective cases, as reflected in the following directive:
Signed statements of witnesses of fact and hearsay notices in accordance with RDC Part 29, shall be extended by four weeks i.e., 4pm on 25 May 2023.
This approach demonstrates the court’s commitment to maintaining a structured evidentiary process, allowing the parties to finalize their witness evidence without the pressure of imminent, unachievable deadlines.
Which specific sections of the Rules of the DIFC Courts (RDC) were invoked to govern the filing of witness replies in CFI 043/2020?
The court specifically cited RDC Rule 23.41 and RDC Part 29 as the governing framework for the filing of witness statements and replies. RDC Rule 23.41 was utilized to mandate the First and Fourth Defendants' reply to the Claimant’s witness statements, while RDC Part 29 provided the overarching procedural rules for the submission of witness statements of fact and hearsay notices. These rules ensure that all parties have a clear understanding of the evidentiary standards and the specific deadlines applicable to their respective filings.
How did the court utilize the RDC Part 29 framework to manage the extended timeline for witness statements in reply?
The court utilized RDC Part 29 to structure the secondary phase of evidentiary production—specifically, the filing of witness statements in reply. By extending the deadline for these replies by four weeks, the court ensured that the parties had adequate time to address the evidence presented in the initial round of witness statements. The court’s order explicitly linked the extension to the requirements of RDC Part 29:
The time frame for any witness statement in reply filed and served in accordance with RDC Part 29, shall be extended by four weeks i.e., 4pm on 25 June 2023.
This systematic application of the RDC ensures that the evidentiary record is developed in a predictable manner, minimizing the risk of procedural disputes during the later stages of the trial.
What was the final disposition of the consent order regarding costs and the procedural timeline?
The court granted the consent order, effectively resetting the procedural clock for the parties. The order mandated that the First and Fourth Defendants file their reply to the Claimant’s witness statement by 5 May 2023. Furthermore, it extended the deadline for signed statements of witnesses of fact and hearsay notices to 25 May 2023, and the deadline for witness statements in reply to 25 June 2023. Regarding the financial implications of the application, the court ordered that there be no order as to costs, reflecting the consensual nature of the procedural adjustments.
How does this consent order influence the expectations for future procedural management in complex DIFC banking litigation?
This order serves as a practical example of how the DIFC Courts manage complex, multi-party litigation through consent-based procedural adjustments. For practitioners, it highlights the importance of utilizing RDC Part 29 and RDC Rule 23.41 to structure evidentiary timelines. It also demonstrates that the court is amenable to reasonable extensions when parties demonstrate a collaborative approach to case management, provided that the extensions are clearly defined and aligned with the RDC. Future litigants should anticipate that the court will prioritize the orderly exchange of evidence and will expect parties to proactively manage their deadlines through formal applications or consent orders when necessary.
Where can I read the full judgment in Bank of Baroda (DIFC Branch) v Neopharma LLC [2023] DIFC CFI 043?
The full text of the consent order is available on the official DIFC Courts website: https://www.difccourts.ae/rules-decisions/judgments-orders/court-first-instance/cfi-0432020-bank-baroda-difc-branch-v-1-neopharma-llc-2-nmc-healthcare-llc-3-new-medical-centre-llc-4-bavaguthu-raghuram-shetty-5
Cases referred to in this judgment:
| Case | Citation | How used |
|---|---|---|
| N/A | N/A | No external case law cited in this order. |
Legislation referenced:
- Rules of the DIFC Courts (RDC): Part 29
- Rules of the DIFC Courts (RDC): Rule 23.41